Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema
MWN-AI** Summary
Iridex Corporation (Nasdaq: IRIX), a leading developer of laser-based medical systems, recently announced the successful enrollment of the first patient in the DAME Trial, an independent, investigator-led study aimed at evaluating the effectiveness of adding MicroPulse® technology to existing anti-VEGF therapies for treating severe diabetic macular edema (DME). Conducted under the guidance of Professor Noemi Lois from Queen's University Belfast, the trial will involve at least 20 clinical sites and a total of 264 participants across the UK.
The DAME Trial seeks to assess the safety, clinical efficacy, cost-effectiveness, and patient acceptability of utilizing subthreshold MicroPulse laser treatment after initial improvements from anti-VEGF therapies. Presently, the standard approach for DME treatment often entails frequent, costly anti-VEGF injections, which can lead to significant patient burden and anxiety, as well as potential complications affecting sight.
Professor Lois emphasized that if the DAME Trial demonstrates that subthreshold MicroPulse treatments can provide similar visual outcomes compared to continued anti-VEGF therapy, it could revolutionize the management of DME. This new pathway may not only minimize the number of injections required but also lessen related risks and costs associated with care.
Iridex’s IQ 577® laser, utilized in its MicroPulse mode, allows for controlled treatment that stimulates the retina's healing response without causing damage to surrounding tissue. Patrick Mercer, Iridex President & CEO, expressed pride in their technology's role in this significant trial, highlighting the potential for advancing diabetic eye care.
The DAME Trial builds on previous research, aiming to ensure the best patient outcomes while developing a strategy for integrating trial results into clinical practice.
MWN-AI** Analysis
Iridex Corporation (Nasdaq: IRIX) has recently taken a significant step forward by announcing the enrollment of the first patient in the DAME Trial, a pivotal study evaluating the effectiveness of MicroPulse technology in treating Diabetic Macular Edema (DME) as an adjunct to anti-VEGF therapy. This development is poised to enhance the company’s position in the ocular treatment market and could have profound implications for its financial performance.
Investors should closely monitor the outcomes of the DAME Trial, particularly given its objective to assess equivalency in visual acuity between treatment pathways. If successful, this could lead to a paradigm shift in DME management, significantly reducing the reliance on costly anti-VEGF injections. This would not only alleviate patient burden but also optimize healthcare spending. The potential for MicroPulse technology to serve as a cost-effective alternative could increase its adoption, leading to a surge in Iridex’s product demand.
Additionally, the backing of the UK’s National Institute for Health Research adds credibility to the trial and offers reassurance regarding the potential for government support in adopting the new treatment protocols. Institutional endorsements typically correlate with a more favorable risk profile for investors.
From a financial perspective, analysts should watch for any updates on trial progress, potential partnerships, or licensing agreements as they unfold. If the DAME Trial demonstrates promising results, a rebound in stock performance could be anticipated, driven by positive market sentiment.
In summary, while Iridex has a solid foundation through its innovative technology, investors should stay cautious and vigilant, as clinical trial outcomes can be unpredictable. A strategic focus on the developments from the DAME Trial may yield lucrative opportunities as the market evaluates the implications of MicroPulse treatment in diabetic eye care.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, announced today that the first patient has been successfully enrolled in the independent, investigator-led DAME Trial to evaluate the clinical efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPulse treatments to anti-vascular endothelial growth factor (anti-VEGF) therapy in patients presenting with severe diabetic macular edema (DME).
Led by Principal Investigator Professor Noemi Lois at Queen’s University Belfast, the study is designed to include at least 20 clinical sites and enroll 264 participants across the United Kingdom with severe DME, defined as having central retinal subfield thickness (CRT) or ?400 ?m once CRT goes below 400?m. The trial is intended to develop a blueprint for the implementation of the new treatment pathway (i.e., adding subthreshold MicroPulse laser only when the CRT is <400?m following anti-VEGFs) into clinical practice, if this is shown to be beneficial to people with DME.
“Current treatment for DME relies heavily on frequent anti-VEGF injections, which are not only expensive and burdensome to patients and healthcare systems but can also lead to patient anxiety along with having potential sight-threatening complications,” said Professor Lois. “DAME may transform the care of people living with diabetes and DME if the trial shows that continuing with subthreshold MicroPulse laser, once the DME has improved following anti-VEGFs, is equivalent in terms of visual outcomes to ongoing anti-VEGF therapy. This strategy may reduce the number of anti-VEGF injections required and, subsequently, risks, inconvenience, and costs to people and health care services. We are excited to have enrolled the first participant in the trial and we are indebted to the National Institute for Health Research (NIHR) in the UK for having funded this trial. We are also very grateful to Iridex and their UK distributor partner, Carleton Optical Equipment Ltd, for supplying the laser systems for this trial.”
The Iridex IQ 577® laser in its MicroPulse® treatment mode, paired with the TxCell® Scanning Delivery Device, allows clinicians to deliver controlled, subthreshold treatment that activates the retina’s natural healing response without causing visible tissue damage.
“We are honored that our IQ 577 laser, MicroPulse, and TxCell technologies are trusted as the exclusive platform for the DAME trial. Our technology enables consistent, safe and effective treatments for DME patients and we are excited to see its additional use investigated in this large-scale trial led by these respected clinicians,” said Patrick Mercer, Iridex President & CEO. “We congratulate Professor Lois and her team for this exciting milestone and commend their efforts to advance diabetic eye care to improve patients’ lives.”
About DAME
The DAME trial “Treatment of severe D iabetic macular oedema with A nti-vascular endothelial growth factor (anti-VEGF) monotherapy versus treatment with Anti-VEGF followed by subthreshold M icropulse las E r” is an independent, investigator-led, pragmatic randomized equivalence trial funded by the Health Technology Assessment of the National Institute for Health Research (HTA-NIHR) in the UK. It is powered to demonstrate equivalence in best-corrected visual acuity outcomes between treatment arms over a 24-month period. Secondary outcomes include quality of life, cost-effectiveness, treatment burden, and patient-reported experience. The trial includes an implementation work package to develop a strategy to implement trial results into clinical practice.
The DAME Trial builds on the success of the DIAMONDS 1-4 study, another independent, investigator-led, multi-center UK trial that demonstrated the safety and effectiveness of subthreshold MicroPulse® laser using the Iridex IQ 577® and TxCell® Scanning Delivery Device in patients presenting with DME of less than 400 ?m in CRT.
Noemi Lois has no conflicts of interest to declare.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com .
Media Contact
Joan Stauffer
jstauffer@iridex.com
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
For more information about Iridex technologies, visit www.iridex.com .
MicroPulse®, IQ 577® and TxCell® are registered trademarks of Iridex. ©2025 Iridex Corporation. All rights reserved.
References
1. Mistry H, Maredza M, Campbell C, Lois N, Diamonds study group. Subthreshold micropulse laser versus standard laser for the treatment of central-involving diabetic macular oedema with central retinal thickness of <400µ: A cost-effectiveness analysis from the DIAMONDS trial . BMJ Open . 2023;13(10):e067684.
2. Lois N, Gardner E, Waugh N, Azuara-Blanco A, Mistry H, McAuley D, Acharya N, Aslam TM, Bailey C, Chong V, Downey L, Eleftheriadis H, Fatum S, George S, Ghanchi F, Groppe M, Hamilton R, Menon G, Saad A, Sivaprasad S, Shiew M, Steel DH, Talks JS, Adams C, Campbell C, Mills M, Clarke M, Group DS. Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): Study protocol for a randomised controlled trial . Trials . 2019;20(1):122.
3. Lois N, Campbell C, Waugh N, Azuara-Blanco A, Maredza M, Mistry H, McAuley D, Acharya N, Aslam TM, Bailey C, Chong V, Downey L, Eleftheriadis H, Fatum S, George S, Ghanchi F, Groppe M, Hamilton R, Menon F, Saad A, Sivaprasad S, Shiew M, DH S, Talks JS, Doherty P, McDowell C, Clarke M. Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: The DIAMONDS non-inferiority rct . Health Technol Assess . 2022;26(50):1-86.
4. Lois N, Campbell C, Waugh N, Azuara-Blanco A, Maredza M, Mistry H, McAuley D, Acharya N, Aslam TM, Bailey C, Chong V, Downey L, Eleftheriadis H, Fatum S, George S, Ghanchi F, Groppe M, Hamilton R, Menon G, Saad A, Sivaprasad S, Shiew M, Steel DH, Talks JS, Doherty P, McDowell C, Clarke M, Diamonds study group. Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): A randomized double-masked non-inferiority clinical trial . Ophthalmology . 2022.
June 2025 PR0001
FAQ**
How will the results of the DAME Trial impact the future market potential and stock performance of IRIDEX Corporation IRIX in the ophthalmology sector?
What strategies does Iridex Corporation IRIX plan to implement to enhance the adoption of their MicroPulse technology following the outcomes of the DAME Trial?
What are the anticipated financial implications for Iridex Corporation IRIX if the DAME Trial demonstrates cost-effectiveness compared to current anti-VEGF treatments?
How might success in the DAME Trial influence investor sentiment and future funding opportunities for Iridex Corporation IRIX in the laser-based medical systems market?
**MWN-AI FAQ is based on asking OpenAI questions about IRIDEX Corporation (NASDAQ: IRIX).
NASDAQ: IRIX
IRIX Trading
-3.53% G/L:
$1.2734 Last:
3,201 Volume:
$1.31 Open:
